OncoMatch/Clinical Trials/NCT03025477
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
Is NCT03025477 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including CC0 - Carboplatin (IV) - Paclitaxel (IV) and CC0 - Cisplatin (IP) - Epirubicin (IV) for ovarian cancer, epithelial.
Treatment: CC0 - Carboplatin (IV) - Paclitaxel (IV) · CC0 - Cisplatin (IP) - Epirubicin (IV) · CC>0 - Carboplatin (IV)- Paclitaxel (IV) · CC>0 - Cisplatin (IP/IV)- Epirubicin (IV) — CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
Excluded: Stage FIGO STAGE IV EXTRA-ABDOMINAL DISEASE
Metastatic disease required
advanced (FIGO stage III or IV)... Exclusion: FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Lab requirements
Blood counts
neutrophils > 1500/mm3, platelets > 150 000/mm3
Kidney function
creatinine clearance mdrd ≥ 60 ml/min
Cardiac function
left ventricular ejection fraction ≥ 50% before chemotherapy initiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify